Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Infusion vs Bolus G-CSF in Pediatric Neutropenia
NCT06145321Phase 4Active, not recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of filgrastim in neutropenia (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Absolute neutrophil counts up to 30 days. Started Nov 2023; status: active, not recruiting.
02
Drugs
filgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT06145321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145321.